Top Story Today
Eli Lilly Drops $3.8 Billion on Psychedelic Medicine. Read That Again.
Eli Lilly is acquiring AtaiBeckley, the psychedelic-derived mental health company, for up to $3.8 billion ($2.8B upfront, $1B in milestone-linked payouts). The deal gives Lilly two clinical-stage programs targeting treatment-resistant depression: an intranasal 5-MeO-DMT formulation heading into Phase 3 and an oral DMT film in Phase 2b. The company that merged to form AtaiBeckley was valued at $390 million less than a year ago, making this nearly a 10x markup. Analysts called it "highly validating" for the entire psychedelic space.
Why it matters: This is the largest big-pharma bet ever placed on psychedelic medicine. Combined with new FDA guidance and a recent executive order on psychedelic drug development, it signals that the field has crossed from counterculture curiosity into a legitimate pharmaceutical arms race.
Read more →Deals and M&A
Two CNS Rivals Just Merged Into a $2.2 Billion Brain Drug Empire
Supernus and Indivior are combining in an all-stock merger of equals, creating a CNS and addiction-treatment powerhouse with 11 marketed drugs and $888 million in adjusted EBITDA. Indivior shareholders get a $1 billion special dividend before closing. Both stocks popped on the news (Supernus up 20%, Indivior up 10%), a rare signal that Wall Street thinks the deal actually creates value rather than destroying it.
Read more →Repligen Bets $1.5 Billion on the Plumbing of Cell Therapy
Repligen is acquiring BioLife Solutions for $1.5 billion, scooping up the freezers, thaw devices, and shipping containers that keep CAR-T therapies alive during transit. BioLife's revenue has been growing strongly, with double-digit year-over-year gains in recent quarters. The bet: as more cell therapies reach commercialization, the real bottleneck isn't science; it's supply chain infrastructure.
Read more →Harrow Grabs the Only Nasal Spray for Dry Eye
Harrow acquired global rights to TYRVAYA, the only FDA-approved nasal spray for dry eye disease, from Viatris for $30 million upfront (up to $100M total). The drug triggers natural tear production through a nerve pathway in the nose. A focused ophthalmology company now owns a first-in-class product that a generics giant had no incentive to champion.
Read more →When Your Partner Goes Broke, You Take the Keys Back
Actimed reclaimed full worldwide rights to its cachexia drug S-oxprenolol after partner Faraday Pharmaceuticals shut down entirely. The original deal was worth up to $123.5 million in milestones. Now Actimed holds an unencumbered global asset in a $2.5 billion market with zero approved therapies that actually reverse muscle wasting.
Read more →IPOs and Funding
A Pain Startup Raised $346 Million on Day One
Latigo Biotherapeutics priced an upsized $345.6 million IPO at the top of its range, making it one of 2026's largest biotech debuts. The company is developing non-opioid NaV1.8 inhibitors for pain, with its lead program heading into Phase 3. From stealth mode to a $600M+ war chest in barely two years.
Read more →Five Biotech IPOs in One Week. The Window Is Wide Open.
BlossomHill Therapeutics raised $150 million in an upsized IPO, capping the busiest week for biotech listings all year. With roughly 20 IPOs raising $6.4 billion in 2026 so far (versus $1.6 billion for all of 2025), the market is selective but firmly open for companies with clinical data and clear commercial paths.
Read more →Ensoma Is Running Out of Lifelines
Ensoma cut staff for the second time in nine months and paused all preclinical programs, betting its survival on a single gene therapy for X-CGD. Despite raising over $200 million in private funding, the platform company now operates in one-asset survival mode, reflecting brutal funding pressures still facing early-stage gene therapy firms.
Read more →Clinical and Regulatory
The Biggest CRO Just Handed Its Trials to an AI
ICON, one of the world's largest CROs, signed a multi-year deal to embed Anthropic's Claude AI across its entire clinical trial operation. The targets: site selection, enrollment prediction, and protocol optimization. With 80% of trials facing recruitment delays, the partnership could reshape how the industry designs and executes studies.
Read more →America's Sunscreen Finally Caught Up to the Rest of the World
The FDA approved bemotrizinol, the first new sunscreen active ingredient in over 20 years. It absorbs both UVA and UVB, stays stable in sunlight (unlike avobenzone), and shows very low skin absorption. DSM-Firmenich gets 18 months of U.S. exclusivity. The approval breaks a decades-long regulatory logjam that left American sunscreens a generation behind.
Read more →